1209012-94-1

Basic information

• Product Name: methyl ((2,3-difluorobenzyl) 5-methylsulfonamido-4,7,8-tri-O-acetyl-9-azido-3,5,9-trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid)onate
• Synonyms: methyl ((2,3-difluorobenzyl) 5-methylsulfonamido-4,7,8-tri-O-acetyl-9-azido-3,5,9-trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid)onate
• CAS NO: 1209012-94-1
• Molecular Weight: 636.585
• Mol File: 1209012-94-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: methyl ((2,3-difluorobenzyl) 5-methylsulfonamido-4,7,8-tri-O-acetyl-9-azido-3,5,9-trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid)onate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl ((2,3-difluorobenzyl) 5-methylsulfonamido-4,7,8-tri-O-acetyl-9-azido-3,5,9-trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid)onate(1209012-94-1)
• EPA Substance Registry System: methyl ((2,3-difluorobenzyl) 5-methylsulfonamido-4,7,8-tri-O-acetyl-9-azido-3,5,9-trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid)onate(1209012-94-1)

Safety Data

• Hazardous Substances Data: 1209012-94-1(Hazardous Substances Data)

Upstream product

• 1209012-90-7 methyl (methyl 5-methylsulfonamido-4,7,8-tri-O-acetyl-9-azido-3,5,9-trideoxy-2-thio-D-glycero-α-D-galacto-2-nonulopyranosid)onate 
• 75853-18-8 (2,3-difluoro-phenyl)-methanol 

Downstream Products

• 1209012-98-5 methyl ((2,3-difluorobenzyl) 5-methylsulfonamido-4,7,8-tri-O-acetyl-9-(4-chlorobenzamido)-3,5,9-trideoxy-D-glycero-r-dgalacto-2-nonulopyranosid)onate 

Relevant articles and documents

Low molecular weight antagonists of the myelin-associated glycoprotein: Synthesis, docking, and biological evaluation

The injured adult mammalian central nervous system is an inhibitory environment, for axon regeneration due to specific inhibitors, among them themyelin-associated glycoprotein (MAG), a member of the Siglec family (sialic-acid binding immunoglobulin-like lectin). In earlier studies, we identified the lead structure 5, which shows a 250-fold improved in vitro affinity for MAG compared to the tetrasaccharide binding epitope of GQ1bα (1), the best physiological MAG ligand described so far. By modifying the 2- and 5-position, the affinity of 5 could be further improved to the nanomolar range (→19a). Docking studies to a homology model of MAG allowed the rationalization of the experimental binding properties. Finally, pharmacokinetic parameters (stability in the cerebrospinal fluid, logD and permeation through the BBB) indicate the drug-like properties of the high-affinity antagonist 19a.